Previous 10 | Next 10 |
Thinly traded nano cap Gemphire Therapeutics (NASDAQ: GEMP ) is down 6% premarket in reaction to results from five-subject open-label proof-of-concept (POC) study evaluating gemcabene in patients with a rare inherited fatty tissue disorder called familial partial lipodystrophy ...
LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the investigator-led Phase 2a study of adult FPLD patients evaluating efficacy...
What’s New? Gemphire Therapeutics ( GEMP ) is a small-cap ($14 million), clinical‑stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia. I have previously highlighted the scientific and managerial errors that have hindered ...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...
Gemphire Therapeutics (NASDAQ: GEMP ): Q4 GAAP EPS of -$0.26 beats by $0.15. More news on: Gemphire Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threaten...
Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...
Gainers: 3Pea International (NASDAQ: TPNL ) +22% . Gemphire Therapeutics (NASDAQ: GEMP ) +19% . Hanesbrands (NYSE: HBI ) +18% . OHR Pharmaceutical (NASDAQ: OHRP ) +16% . Chipotle Mexican Grill (NYSE: CMG ) +14% . ION Geophysical (NYSE: IO ) +15% . CSG Systems International (NAS...
The Investment Thesis Update Gemphire ( GEMP ) is a small cap ($15M) clinical stage biopharmaceutical company focused on the clinical development of therapies for cardiometabolic disorders, including dyslipidemia and NASH. Gemcabene (CI-1027 or PD 72953) was in clinical development as a li...
News, Short Squeeze, Breakout and More Instantly...
Gemphire Therapeutics Inc. Company Name:
GEMP Stock Symbol:
NASDAQ Market:
Gemphire Therapeutics Inc. Website:
ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing cond...
ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all ...
LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiova...